BIOFIL CHEM & PHARMA LTD (BIOFILCHEM)

NSE: ₹35.17
BSE: ₹34.45
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

Submission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

2026-06-01 12:20:29
Audited Financial Result For The Financial Year Ended 31.03.2026

Audited Financial Result for the Financial Year ended 31.03.2026

2026-05-30 19:05:29
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 30Th May, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2026-05-30 18:51:34
Compliances-Reg.24(A)-Annual Secretarial Compliance

Submission of Annual Secretarial Compliance Report for the Financial year ended 31st March 2026

2026-05-23 12:50:43
Board Meeting Intimation for Meeting Of Board Of The Directors (Serial No.01/2026-27) Of The Company Scheduled To Be Held On Saturday, 30Th May, 2026.

the Audited Financial Results of the Company for the fourth Quarter as well as Financial Year ended on 31st March, 2026.

2026-05-21 17:41:07
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Intimation To The Shareholders Holding Shares In Physical Mode For Mandatory Furnishing Of PAN, KYC Details, Bank Account Details, Nomination And Other Details.

The Company hereby submit drafts intimation letter sent to holders of Physical shares of the company for updating PAN, KYC, Nomination and other details in accordance with applicable SEBI Circulars in terms of provisions of Reg.30 of SEBI (LODR) Regulations, 2015 from time to time.

2026-05-05 16:28:45
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBiofil Chemicals & Pharmaceuticals Ltd 2CIN NO.L24233MP1985PLC002709 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.02 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Apoorv Jain Designation: Company Secretary and Compliance Officer EmailId: bcplcompliance@gmail.com Name of the Chief Financial Officer: Pavan Singh Rajput Designation: Chief Financial Officer EmailId: pawan90rajkam@gmail.com Date: 10/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

2026-04-10 12:44:27
Announcement under Regulation 30 (LODR)-Newspaper Publication

Submission of Publication in Newspaper pursuant to SEBI circular for Special Window for Transfer and Dematerialisation of Physcial Securities.

2026-04-03 12:54:37
Intimation Regarding SEBI Circular Dated January 30, 2026 – Ease Of Doing Investment – Special Window For Transfer And Dematerialisation Of Physical Securities

Intimation regarding SEBI Circular dated January 30, 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .

2026-04-02 15:48:47
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended on 31st March, 2026

2026-04-01 12:58:39

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 2.43 17.37 5.03 15.20 8.44 2.41 14.20 8.35 6.43 13.54 0.86 7.57
YOY Revenue Growth % -80.22% 562.99% 236.69% 11.66% 246.97% -86.11% 182.13% -45.07% -23.82% 461.25% -93.97% -9.4%
Other Income 0.02 0.03 0.03 0.41 0.03 0.02 0.02 0.24 2.83 0.06 0.08 0.11
Total Income 2.46 17.40 5.06 15.61 8.47 2.43 14.22 8.59 9.26 13.60 0.93 7.67
Total Expenses + 2.13 17.25 4.95 15.33 8.24 2.40 14.00 8.33 6.50 13.49 0.83 7.21
Cost of Materials Consumed 1.36 12.92 1.66 -10.68 0.69 0.42 2.13 2.08 1.17 1.18 3.23 1.80
Employee Benefit Expense 0.16 0.16 0.15 0.20 0.14 0.18 0.21 0.25 0.21 0.18 0.19 0.22
Other Expenses 0.24 0.27 0.23 0.30 0.28 0.14 0.16 0.34 0.28 0.15 0.22 0.33
Operating Profit 0.30 0.12 0.09 -0.13 0.20 0.02 0.20 0.02 -0.07 0.05 0.03 0.36
OPM % 12.3% 0.7% 1.7% -0.9% 2.4% 0.7% 1.4% 0.2% -1.1% 0.4% 3.3% 4.8%
Profit Before Tax + 0.32 0.15 0.11 0.27 0.23 0.03 0.22 0.25 2.76 0.11 0.11 0.47
Tax Expense 0.08 0.03 0.02 0.03 0.06 0.01 0.06 0.05 0.35 0.03 0.03 0.26
Tax % 24.7% 19.6% 17.7% 9.5% 25.7% 25.6% 25.8% 21.4% 12.7% 25.2% 25.8% 54.7%
Profit After Tax 0.24 0.12 0.09 0.25 0.17 0.02 0.16 0.20 2.41 0.08 0.08 0.21
EPS (Basic) 0.15 0.08 0.06 0.15 0.10 0.01 0.10 0.12 1.48 0.05 0.05 0.13

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 28.40 33.40 40.04 30.04 22.38 35.75 29.69
YOY Revenue Growth % -14.99% -16.57% 33.29% 34.19% -37.39% 20.41% -
Other Income 3.08 0.31 0.49 0.10 0.15 0.80 0.17
Total Income 31.48 33.71 40.53 30.13 22.53 36.55 29.86
Total Expenses + 28.03 32.97 39.66 29.34 21.52 34.63 6.61
Cost of Materials Consumed 7.38 5.31 5.26 3.92 2.27 6.85 4.06
Employee Benefit Expense 0.80 0.79 0.67 0.62 0.79 0.75 0.86
Other Expenses 0.99 0.92 1.04 0.82 0.80 0.97 1.69
Operating Profit 0.37 0.43 0.38 0.70 0.86 1.12 23.08
OPM % 1.3% 1.3% 0.9% 2.3% 3.9% 3.1% 77.7%
Profit Before Exceptional 3.45 0.74 0.87 0.79 1.01 1.92 1.46
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 3.45 0.74 0.87 0.79 1.01 1.92 1.46
Tax Expense 0.66 0.18 0.16 0.23 0.32 0.68 0.26
Tax % 19.2% 24.2% 18% 29.3% 31.2% 35.2% 17.5%
Profit After Tax 2.79 0.56 0.71 0.56 0.70 1.25 1.21
EPS (Basic) 1.71 0.34 0.44 0.29 0.44 0.76 0.76

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 6.99 8.41 8.68 9.00 9.42 9.78 0.00
Property, Plant & Equipment 6.94 8.34 8.62 9.00 9.42 9.78 0.00
Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current Assets + 35.86 42.55 38.41 22.41 9.31 23.46 0.00
Inventories 4.00 3.34 2.55 1.21 1.29 4.34 0.00
Trade Receivables 27.59 38.32 33.03 20.50 7.17 17.22 0.00
Cash and Cash Equivalents 0.06 0.13 0.09 0.03 0.09 0.01 0.00
Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 21.56 18.78 18.20 17.30 16.84 16.13 0.00
Equity Share Capital 16.27 16.27 16.27 16.27 16.27 16.27 0.00
Other Equity 5.29 2.51 1.93 1.03 0.56 -0.14 0.00
Non-Current Liabilities 0.59 0.33 0.36 0.38 0.40 0.36 0.00
Current Liabilities 20.69 31.85 28.52 13.73 1.49 16.75 0.00
Total Liabilities 21.28 32.18 28.88 14.10 1.89 17.11 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities -0.60 -1.92 2.39 -0.11 -0.22 1.11 0.00
Cash from Investing Activities 1.14 -0.10 -0.02 -0.01 -0.07 -0.10 0.00
Cash from Financing Activities 2.54 0.00 -0.12 0.02 -0.01 -0.83 0.00
Net Increase/Decrease in Cash 3.07 -2.03 2.25 -0.11 -0.30 0.18 0.00